Is adjuvant chemotherapy necessary for early gastric cancer?

Yu MeiTienan FengMin YanZhenggang Zhu Zhenglun Zhu

Published in: Cancer biology & medicine (2021)

Curative surgery only was adequate for patients with pT1N0 and pT1N1. Xelox showed no survival benefits for pT1N2 patients. Therefore, S-1 is the optimal choice for pT1N2 patients, when considering adverse effects. Xelox is recommended for pT1N3 patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
atrial fibrillation
surgical site infection